Page 7 - Yongjun Liu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Synaffix B V : Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent s Pipeline

Synaffix B V : Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent s Pipeline
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Hong kongAdimab incyteYongjun liuMelanie toyne sewell katie duffellAnthony deboerEli lillyNational reimbursement drug listMd anderson cancer centerPlatform technologyInnovent biologics incBusiness developmentMersana therapeuticsBiogeneration venturesMain boardStock exchangeHong kong limited

Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma

Share this article Share this article SAN FRANCISCO and SUZHOU, China, June 27, 2021 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab biosimilar injection) as a first-line treatment for people with advanced or unresectable hepatocellular carcinoma (HCC). This is the first regulatory approval of a PD-1 inhibitor-based combination therapy for the first-line treatment for HCC.

United statesHong kongAdimab incyteYongjun liuEli lillyZhongshan hospital of fudan universityMd anderson cancer centerData monitoring committeeNational medical products administrationChina national reimbursement drug listIncyte corporationRadiographic review committeeInnovent biologics incInnovent biologicsNew drug applicationIndependent data monitoring committee

Innovent Biologics : and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality. | June 3, 2021

United statesHong kongPabout sintilimabAdimab incyteYongjun liuCaicun zhouEli lillyClinical development of innoventOncology department at shanghai pulmonary hospitalMd anderson cancer centerAffairs centerNational reimbursement drug listHead of lilly china drug developmentNational medical products administrationChina national reimbursement drug listInnovent biologics inc

U S FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

U S FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongAdimab incyteAnne whiteYongjun liuEli lillyCompany forwardDrug administrationMd anderson cancer centerAdvisory committeeExchange commissionChina national reimbursement drug listRadiographic review committeeInnovent biologics incInnovent biologicsBiologics license application

U S FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

U S FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.